283 related articles for article (PubMed ID: 34898139)
1. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF
N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
3. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
4. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF
Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320
[TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
Goyal S; Tisdale J; Schmidt M; Kanter J; Jaroscak J; Whitney D; Bitter H; Gregory PD; Parsons G; Foos M; Yeri A; Gioia M; Voytek SB; Miller A; Lynch J; Colvin RA; Bonner M
N Engl J Med; 2022 Jan; 386(2):138-147. PubMed ID: 34898140
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy in a Patient with Sickle Cell Disease.
Ribeil JA; Hacein-Bey-Abina S; Payen E; Magnani A; Semeraro M; Magrin E; Caccavelli L; Neven B; Bourget P; El Nemer W; Bartolucci P; Weber L; Puy H; Meritet JF; Grevent D; Beuzard Y; Chrétien S; Lefebvre T; Ross RW; Negre O; Veres G; Sandler L; Soni S; de Montalembert M; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2017 Mar; 376(9):848-855. PubMed ID: 28249145
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Herring WL; Gallagher ME; Shah N; Morse KC; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B
Pharmacoeconomics; 2024 Jun; 42(6):693-714. PubMed ID: 38684631
[TBL] [Abstract][Full Text] [Related]
9. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
[TBL] [Abstract][Full Text] [Related]
10. Post-Transcriptional Genetic Silencing of
Esrick EB; Lehmann LE; Biffi A; Achebe M; Brendel C; Ciuculescu MF; Daley H; MacKinnon B; Morris E; Federico A; Abriss D; Boardman K; Khelladi R; Shaw K; Negre H; Negre O; Nikiforow S; Ritz J; Pai SY; London WB; Dansereau C; Heeney MM; Armant M; Manis JP; Williams DA
N Engl J Med; 2021 Jan; 384(3):205-215. PubMed ID: 33283990
[TBL] [Abstract][Full Text] [Related]
11. LentiGlobin Administration to Sickle Cell Disease Patients: Effect on Serum Markers and Vaso-Occlusive Crisis.
Kumar H; Sharma V; Wadhwa SS; Gowda DM; Kaushik S; Joseph AM; Karas M; Quinonez J; Furiato A
Cureus; 2024 Jan; 16(1):e51881. PubMed ID: 38327940
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 Editing of the
Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
[TBL] [Abstract][Full Text] [Related]
13. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
14. A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice.
Wang X; McKillop WM; Dlugi TA; Faber ML; Alvarez-Argote J; Chambers CB; Wilber A; Medin JA
J Gene Med; 2024 Jan; 26(1):e3567. PubMed ID: 37455676
[TBL] [Abstract][Full Text] [Related]
15. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies.
Breda L; Ghiaccio V; Tanaka N; Jarocha D; Ikawa Y; Abdulmalik O; Dong A; Casu C; Raabe TD; Shan X; Danet-Desnoyers GA; Doto AM; Everett J; Bushman FD; Radaelli E; Assenmacher CA; Tarrant JC; Hoepp N; Kurita R; Nakamura Y; Guzikowski V; Smith-Whitley K; Kwiatkowski JL; Rivella S
Mol Ther; 2021 Apr; 29(4):1625-1638. PubMed ID: 33515514
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.
Bank A; Dorazio R; Leboulch P
Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679
[TBL] [Abstract][Full Text] [Related]
20. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
